pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Dexlansoprazole
drug
save

dexlansoprazole DR

Marketedupdated 3mo ago
by TWi Pharmaceuticals USA Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval2 co-mentions · 1 sources
  • drugDEXLANSOPRAZOLE1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

all catalysts(1)

approval · 1
Nov 12, 2025
approval
9mo ago
DEXLANSOPRAZOLE — FDA approval
dexlansoprazole DR
→

Trials studying dexlansoprazole DR

  • phase2A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Oldactive not recruitingn=76
  • phase2A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Oldrecruitingn=70
  • phase1Effect of Dexlansoprazole on Bone Homeostasiscompletedn=115
  • phase1Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.completedn=60

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 27, 2026
38 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (31)

  • Mar 5, 2032method-of-use (U-1805)US 9233103
  • Mar 5, 2032method-of-use (U-1805)US 9233103
  • Sep 17, 2030patentUS 8173158*PED4.1y
  • Sep 17, 2030patentUS 8173158*PED4.1y
  • Mar 17, 2030method-of-use (U-950)US 81731583.6y
  • Mar 17, 2030method-of-use (U-949)US 81731583.6y
  • Mar 10, 2029formulationUS 92419102.6y
  • Jul 11, 2028patentUS 8871273*PED1.9y
  • Jan 11, 2028formulationUS 88712731.4y
  • Jan 11, 2028formulationUS 88712731.4y
  • Jan 11, 2028formulationUS 88712731.4y
  • Mar 27, 2027patentUS 8105626*PED219d
  • Mar 27, 2027patentUS 8105626*PED219d
  • Feb 2, 2027patentUS 7790755*PED166d
  • Feb 2, 2027patentUS 7790755*PED166d
  • Sep 27, 2026formulationUS 810562638d
  • Sep 27, 2026formulationUS 810562638d
  • Aug 2, 2026formulationUS 7790755
  • Aug 2, 2026formulationUS 7790755
  • Jul 17, 2026patentUS 8461187*PED
  • Jul 17, 2026patentUS 8461187*PED
  • Jul 17, 2026patentUS 8461187*PED
  • Feb 24, 2026formulationUS 9011926
  • Feb 24, 2026formulationUS 9011926
  • Feb 24, 2026formulationUS 9011926
  • Jan 17, 2026formulationUS 8461187
  • Jan 17, 2026formulationUS 8461187
  • Jan 17, 2026formulationUS 8461187
  • Jan 17, 2026formulationUS 9238029
  • Jan 17, 2026formulationUS 9238029
  • Jan 17, 2026formulationUS 9238029

News(0)

no news has mentioned this drug yet

brand
Dexlansoprazole
generic
dexlansoprazole
indication
Acid Indigestion (Heartburn/Pyrosis)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?